Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
nonalcoholic steatohepatitis (NASH)
Pharma
Madrigal's first-ever MASH drug beats sales projections again
Addressing the potential competition from semaglutide, Madrigal's CEO said Novo is gunning for “multiples” the size of Rezdiffra’s target population.
Angus Liu
May 2, 2025 11:00am
'No weakness' in Madrigal's Rezdiffra MASH launch, says CEO
Feb 27, 2025 11:19am
Novo Nordisk's semaglutide delivers in phase 3 MASH study
Nov 1, 2024 10:38am
Madrigal's MASH drug Rezdiffra 'blew away' expectations in Q3
Oct 31, 2024 3:24pm
Lilly, Gilead-Yuhan, Leqembi—Fierce Pharma Asia
Oct 18, 2024 8:20am
Madrigal maps out 'Way Forward' for MASH patients with Rezdiffra
Sep 6, 2024 6:30am
